ANDA 202275, held by Avet Lifesciences. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 202275 (Vancomycin Hydrochloride), held by Avet Lifesciences, was first approved by FDA on Oct 31, 2013, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2013 | Original application | Approved | None posted |
| Vancomycin HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Discontinued |
| Vancomycin HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Discontinued |
| May 25, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 22, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 22, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 22, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 31, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters